Dr. Pan Zheng leads global clinical development at OncoC4, overseeing the execution of the company’s clinical development strategy across multiple early to late-stage programs. She is a co-founder and Chief Medical Officer of OncoC4, Inc., continuing the leadership she established at OncoImmune, where she served as co-founder and Chief Medical Officer and led clinical development through all stages until the company’s successful acquisition by Merck & Co. in 2020.

Prior to industry, Dr. Zheng spent more than 20 years as a professor at leading academic medical centers, including The Ohio State University Medical Center, the University of Michigan, Children’s National Medical Center, and the University of Maryland School of Medicine. She has authored over 150 peer-reviewed publications and is internationally recognized for her contributions to immunology and translational medicine. 

Dr. Zheng co-discovered the CD24–Siglec‑10 immune checkpoint (Science, 2009), a foundational discovery that led to the invention of CD24Fc and its advancement into Phase I–III clinical trials demonstrating safety and therapeutic efficacy across multiple indications. At OncoC4, she drove ONC‑392 (gotistobart) from first-in-human studies to Phase III development in under three years, despite the challenges of the COVID-19 pandemic.

She is trained in anatomic and clinical pathology and is board-certified by the American Board of Pathology. In 2022, Dr. Zheng was inducted into the College of Fellows of the American Institute for Medical and Biological Engineering (AIMBE) in recognition of her outstanding contributions to immune checkpoint regulation and drug development in cancer immunotherapy and COVID-19 therapeutics.